This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Amarin: Fish-Oil Pill Serves Up Second Study Win

Stocks in this article: AMRN GSK PFE AZN

MYSTIC, Conn. ( TheStreet) -- Amarin's (AMRN) medicinal-grade fish oil drug AMR101 significantly lowered triglyceride levels without raising "bad" LDL cholesterol, according to results of a late-stage study reported Monday.

That's the exact same lede I used last November when Amarin reported strongly positive results from the first phase III study of AMR101 known as "Marine." Today's data from the second phase III "Anchor" study of AMR101 are equally positive and impressive -- perhaps even more so because the patients enrolled were already being treated with cholesterol-lowering statin drugs like Zocor, Crestor and Lipitor.

Amarin shares were up 65% to $14.50 in pre-market trading Monday. The stock closed Friday at $8.77.

Amarin plans to seek U.S. approval of AMR101 before the end of the third quarter. AMR101, if approved, has the potential to be a blockbuster drug generated well over $1 billion in annual sales.

AMR101 is an ultra-purified form of the omega-3 fatty acid known as Ethyl EPA.

The Anchor study enrolled patients with "mixed" trigylceride baseline levels (200-500 mg/dl) who were also on statin therapy. This is a patient population about 10 times larger than the patient population targeted in the Marine study, in which patients had very high, uncontrollable trigylceride levels.

Treatment with a 4 gram and 2 gram doses of AMR101 resulted in placebo-adjusted reductions in triglyceride levels of 21.5% and 10.1%, respectively. These results were statistically significant and met the primary endpoint of the Anchor study, Amarin said.

Just as importantly, patients treated with the 4-gram dose of AMR101 reported a 6.2% reduction in levels of LDL cholesterol, demonstrating statistically significant superiority over placebo. The lower 2-gram dose of AMR101 demonstrated a 3.6% reduction in LDL cholesterol versus placebo but this result was not statistically significant.

"I am very impressed with the performance of AMR101," said Dr. Christie Ballantyne of Houston's Methodist DeBakey Heart and Vascular Center and the principal investigator of the Anchor trial," in a statement. "In particular, whereas current triglyceride-lowering drugs may raise LDL-C and causes patient treatment concerns, AMR101 demonstrated a decrease in LDL-C beyond the decrease created by statin therapy."

GlaxoSmithKline (GSK) sells a competing prescription fish oil pill known as Lovaza that generates close to $1 billion in annual sales. Lovaza, however, isn't used to treat patients with mixed triglyceride levels because the drug causes elevations of LDL or "bad" cholesterol levels.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs